Latest Press Releases View all May 04, 2026 Vertex Reports First Quarter 2026 Financial Results Apr 06, 2026 Vertex to Announce First Quarter 2026 Financial Results on May 4th Apr 01, 2026 Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States View all Featured Media Library Items View all Reshma Kewalramani, M.D. Chief Executive Officer and President Download Duncan McKechnie Executive Vice President and Chief Commercial Officer Download Vertex International Headquarters – Lobby Download View all
Apr 01, 2026 Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States